Shenzhen Salubris Pharmaceuticals Future Growth

Future criteria checks 2/6

Shenzhen Salubris Pharmaceuticals is forecast to grow earnings and revenue by 17.2% and 15.8% per annum respectively. EPS is expected to grow by 17.2% per annum. Return on equity is forecast to be 9.1% in 3 years.

Key information

17.2%

Earnings growth rate

17.2%

EPS growth rate

Pharmaceuticals earnings growth	19.4%
Revenue growth rate	15.8%
Future return on equity	9.1%
Analyst coverage	Low
Last updated	31 Aug 2024

Recent future growth updates

Recent updates

We Think That There Are More Issues For Shenzhen Salubris Pharmaceuticals (SZSE:002294) Than Just Sluggish Earnings

Sep 02

What Shenzhen Salubris Pharmaceuticals Co., Ltd.'s (SZSE:002294) P/E Is Not Telling You

Aug 23

Are Investors Undervaluing Shenzhen Salubris Pharmaceuticals Co., Ltd. (SZSE:002294) By 21%?

Aug 02

Shenzhen Salubris Pharmaceuticals Co., Ltd.'s (SZSE:002294) Share Price Not Quite Adding Up

May 22

A Look At The Fair Value Of Shenzhen Salubris Pharmaceuticals Co., Ltd. (SZSE:002294)

Apr 17

Is Shenzhen Salubris Pharmaceuticals (SZSE:002294) A Risky Investment?

Feb 28

Earnings and Revenue Growth Forecasts

SZSE:002294 - Analysts future estimates and past financials data (CNY Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	5,483	896	761	1,212	4
12/31/2025	4,678	737	664	867	4
12/31/2024	4,001	633	499	1,096	4
6/30/2024	3,724	587	289	1,019	N/A
3/31/2024	3,569	569	262	944	N/A
12/31/2023	3,365	580	168	839	N/A
9/30/2023	3,390	577	121	806	N/A
6/30/2023	3,498	627	388	916	N/A
3/31/2023	3,434	611	402	931	N/A
1/1/2023	3,482	637	372	971	N/A
9/30/2022	3,419	681	481	1,032	N/A
6/30/2022	3,350	645	768	1,276	N/A
3/31/2022	3,228	616	726	1,231	N/A
1/1/2022	3,058	534	702	1,185	N/A
9/30/2021	2,792	185	510	1,063	N/A
6/30/2021	2,579	101	40	597	N/A
3/31/2021	2,638	66	341	878	N/A
12/31/2020	2,739	61	732	1,374	N/A
9/30/2020	3,041	266	811	1,408	N/A
6/30/2020	3,650	279	1,171	1,774	N/A
3/31/2020	4,148	544	1,043	1,680	N/A
12/31/2019	4,470	715	1,049	1,507	N/A
9/30/2019	4,681	1,025	1,067	1,479	N/A
6/30/2019	4,741	1,301	1,238	1,599	N/A
3/31/2019	4,714	1,364	1,178	1,475	N/A
12/31/2018	4,652	1,458	1,008	1,341	N/A
9/30/2018	4,587	1,508	1,174	1,494	N/A
6/30/2018	4,386	1,511	940	1,280	N/A
3/31/2018	4,308	1,491	N/A	1,336	N/A
12/31/2017	4,154	1,452	N/A	1,458	N/A
9/30/2017	4,106	1,451	N/A	1,406	N/A
6/30/2017	3,976	1,432	N/A	1,507	N/A
3/31/2017	3,891	1,415	N/A	1,557	N/A
12/31/2016	3,833	1,396	N/A	1,435	N/A
9/30/2016	3,739	1,380	N/A	1,503	N/A
6/30/2016	3,711	1,341	N/A	1,340	N/A
3/31/2016	3,610	1,310	N/A	1,170	N/A
12/31/2015	3,478	1,266	N/A	1,056	N/A
9/30/2015	3,467	1,217	N/A	972	N/A
6/30/2015	3,237	1,166	N/A	921	N/A
3/31/2015	3,015	1,102	N/A	978	N/A
12/31/2014	2,883	1,042	N/A	982	N/A
9/30/2014	2,686	989	N/A	877	N/A
6/30/2014	2,570	933	N/A	909	N/A
3/31/2014	2,450	883	N/A	761	N/A
12/31/2013	2,327	830	N/A	669	N/A
9/30/2013	2,108	793	N/A	619	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 002294's forecast earnings growth (17.2% per year) is above the savings rate (2.9%).

Earnings vs Market: 002294's earnings (17.2% per year) are forecast to grow slower than the CN market (23% per year).

High Growth Earnings: 002294's earnings are forecast to grow, but not significantly.

Revenue vs Market: 002294's revenue (15.8% per year) is forecast to grow faster than the CN market (13.2% per year).

High Growth Revenue: 002294's revenue (15.8% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 002294's Return on Equity is forecast to be low in 3 years time (9.1%).

Shenzhen Salubris Pharmaceuticals Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Price target increased by 7.2% to CN¥37.50

Consensus EPS estimates fall by 11%

Price target increased to CN¥30.65

Consensus forecasts updated

Price target increased to CN¥25.35

Price target decreased to CN¥20.00

Recent updates

We Think That There Are More Issues For Shenzhen Salubris Pharmaceuticals (SZSE:002294) Than Just Sluggish Earnings

Price target increased by 7.2% to CN¥37.50

Second quarter 2024 earnings released: EPS: CN¥0.13 (vs CN¥0.11 in 2Q 2023)

What Shenzhen Salubris Pharmaceuticals Co., Ltd.'s (SZSE:002294) P/E Is Not Telling You

Are Investors Undervaluing Shenzhen Salubris Pharmaceuticals Co., Ltd. (SZSE:002294) By 21%?

Shenzhen Salubris Pharmaceuticals Co., Ltd. to Report First Half, 2024 Results on Aug 27, 2024

Shenzhen Salubris Pharmaceuticals Co., Ltd.'s (SZSE:002294) Share Price Not Quite Adding Up

First quarter 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.19 in 1Q 2023)

A Look At The Fair Value Of Shenzhen Salubris Pharmaceuticals Co., Ltd. (SZSE:002294)

Shenzhen Salubris Pharmaceuticals Co., Ltd. to Report Q1, 2024 Results on Apr 23, 2024

Shenzhen Salubris Pharmaceuticals Co., Ltd., Annual General Meeting, Apr 22, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Is Shenzhen Salubris Pharmaceuticals (SZSE:002294) A Risky Investment?

Investor sentiment improves as stock rises 17%

Shenzhen Salubris Pharmaceuticals Co., Ltd. to Report Fiscal Year 2023 Results on Mar 26, 2024

Consensus EPS estimates fall by 11%

Third quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.18 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.11 (vs CN¥0.095 in 2Q 2022)

Upcoming dividend of CN¥0.50 per share at 1.4% yield

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target increased to CN¥30.65

Consensus forecasts updated

Price target increased to CN¥25.35

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.095 (vs CN¥0.073 in 2Q 2021)

Price target decreased to CN¥20.00

Consensus revenue estimates increase by 10%

High number of new directors

Shenzhen Salubris Pharmaceuticals Co., Ltd. Announces Final Dividend on A Shares for the Year 2021, Payable on April 27, 2022

Shenzhen Salubris Pharmaceuticals Co., Ltd. Approves Cash Dividend for 2021

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Shenzhen Salubris Pharmaceuticals Co., Ltd., Annual General Meeting, Apr 18, 2022

Shenzhen Salubris Pharmaceuticals Co., Ltd. Proposes Dividend for 2021

Consensus EPS estimates fall by 13%

Price target decreased to CN¥25.00

Third quarter 2021 earnings released: EPS CN¥0.17 (vs CN¥0.07 in 3Q 2020)

Price target decreased to CN¥22.60

Second quarter 2021 earnings released: EPS CN¥0.073 (vs CN¥0.047 in 2Q 2020)

ROSY METRO LIMITED acquired a 13.78% stake in M.A. Med Alliance S.A from Shenzhen Salubris Pharmaceuticals Co., Ltd. (SZSE:002294) for $45 million.

First quarter 2021 earnings released: EPS CN¥0.15 (vs CN¥0.14 in 1Q 2020)

Consensus forecasts updated

Consensus forecasts updated

Consensus revenue estimates fall to CN¥3.35b

Full year 2020 earnings released: EPS CN¥0.06 (vs CN¥0.68 in FY 2019)

New 90-day high: CN¥38.86

New 90-day high: CN¥32.23

Price target raised to CN¥22.60

New 90-day low: CN¥27.10

Analysts lower EPS estimates to CN¥0.45

New 90-day low: CN¥29.41

Analysts increase EPS estimates to CN¥0.62

Third quarter earnings released

Annual earnings released: Earnings miss expectations

New 90-day low: CN¥31.70

Shenzhen Salubris Pharmaceuticals Co., Ltd. to Report Q3, 2020 Results on Oct 23, 2020

Shenzhen Salubris Pharmaceuticals Co., Ltd. announced that it expects to receive CNY 2 billion in funding

Analysts update estimates

New 90-day high - CN¥41.20

Price target raised to CN¥17.84

Earnings released

Shenzhen Salubris Pharmaceuticals Co., Ltd. to Report First Half, 2020 Results on Aug 27, 2020

Shenzhen Salubris Pharmaceuticals Co., Ltd. (SZSE:002294) completed the acquisition of remaining 15.7% stake in Salubris (Suzhou) Pharmaceutical Co., Ltd. from a group of shareholders.

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies